Muhammad Younus, MD, PHD

Pfizer Inc

Poster(s):

• (035) Safety Events in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis Exposed to Tofacitinib (Xeljanz) or Biologics: Real-World Data from the CARRA Registry
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (307) Long-term Safety and Effectiveness of Taliglucerase-alfa for Gaucher disease (GD): An International, Prospective 10-Year Follow Up Drug Registry Study (TALIAS)
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (336) Current Approaches in Post-Approval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published Literature
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (351) Preliminary Findings from a Feasibility and Capacity Assessment of Truveta® Studio using Flu Vaccine as Example: A Near Real-Time Electronic Health Records Database with Potential to Monitor Post-Approval Vaccine Safety
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST